Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

NCT ID: NCT03346824

Last Updated: 2018-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-15

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiogenic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18
* Patient requiring the need for short-term assistance
* Patient who has agreed to use his medical data for research purposes

Exclusion Criteria

* Refusal to participate in the study
* Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant
* Non-cardiac indications of assistance (indication of pulmonary replacement)
* Subject under guardianship or curatorship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service Réanimation chirurgicale cardiovasculaire-NHC

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gharib AJOB, MD

Role: CONTACT

33 3 69 55 15 70

Guillaume HAFFNER, MD

Role: CONTACT

33 3 69 55 15 70

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gharib AJOB, MD

Role: primary

33 3 69 55 15 70

Guillaume HAFFNER, MD

Role: backup

33 3 69 55 15 70

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6946

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.